



<https://helda.helsinki.fi>

Validation of the X-ray microtomography in the assessment of duodenal morphometry and surface area in celiac disease

Virta, Johannes

2022-09-23

Virta, J, Hannula, M, Lindfors, K, Tamminen, I, Taavela, J, Huhtala, H, Kaukinen, K, Saavalainen, P, Hyttinen, J & Kurppa, K 2022, ' Validation of the X-ray microtomography in the assessment of duodenal morphometry and surface area in celiac disease ', *Frontiers in Immunology*, vol. 13, 945197. <https://doi.org/10.3389/fimmu.2022.945197>

<http://hdl.handle.net/10138/353503>

<https://doi.org/10.3389/fimmu.2022.945197>

cc_by

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Validation of the X-ray microtomography in the assessment of duodenal morphometry and surface area in celiac disease

OPEN ACCESS

EDITED BY

Marco Vincenzo Lenti,
University of Pavia, Italy

REVIEWED BY

Annalisa Schieppati,
Università degli Studi di Pavia, Italy
Mariantonia Maglio,
University of Naples Federico II, Italy

*CORRESPONDENCE

Kalle Kurppa
kalle.kurppa@tuni.

SPECIALTY SECTION

This article was submitted to
Mucosal Immunity,
a section of the journal
Frontiers in Immunology

RECEIVED 16 May 2022

ACCEPTED 01 September 2022

PUBLISHED 23 September 2022

CITATION

Virta J, Hannula M, Lindfors K,
Tamminen I, Taavela J, Huhtala H,
Kaukinen K, Saavalainen P, Hyttinen J
and Kurppa K (2022) Validation of the
X-ray microtomography in the
assessment of duodenal morphometry
and surface area in celiac disease.
Front. Immunol. 13:945197.
doi: 10.3389/fimmu.2022.945197

COPYRIGHT

© 2022 Virta, Hannula, Lindfors,
Tamminen, Taavela, Huhtala, Kaukinen,
Saavalainen, Hyttinen and Kurppa. This is
an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.

Johannes Virta^{1,2}, Markus Hannula³, Katri Lindfors⁴,
Ilmari Tamminen³, Juha Taavela⁴, Heini Huhtala⁵,
Katri Kaukinen^{4,6}, Päivi Saavalainen⁷,
Jari Hyttinen³ and Kalle Kurppa^{1,2,4,8*}

¹Tampere Center for Child Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland, ²Department of Pediatrics, Tampere University Hospital, Tampere, Finland, ³Computational Biophysics and Imaging Group, The Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland, ⁴Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland, ⁵Faculty of Social Sciences, Tampere University, Tampere, Finland, ⁶Department of Internal Medicine, Tampere University Hospital, Tampere, Finland, ⁷Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland, ⁸The University Consortium of Seinäjoki and Seinäjoki Central Hospital, Seinäjoki, Finland

Background: Duodenal histology remains the diagnostic reference standard in celiac disease. However, traditional methods have suboptimal sensitivity and reproducibility for early mucosal changes and research purposes. We validated a recently introduced micro-CT imaging method for an accurate digital evaluation of duodenal histomorphometry and mucosal surface areas.

Methods: Endoscopic biopsies from 58 individuals were utilized for the micro-CT imaging, selecting histological changes ranging from normal to severely damaged mucosa. The imaging protocol was optimized for practicability and resolution. The Bland–Altman method was applied to test intra- and interobserver variations in the blinded measurements.

Results: The 3D micro-CT reconstructions enabled easy and precise digital cutting with optimal orientation and computer-assisted measurement of the surface area. Intraobserver analysis of morphological measurements showed a mean difference of 0.011 with limits of agreement (LA) from -0.397 to 0.375 and a standard deviation (SD) of 0.197. The corresponding figures for interobserver analysis were 0.080, from -0.719 to 0.537 and 0.320, respectively. The intraclass correlation coefficients (ICC) for the intraobserver and interobserver variations were 0.981 and 0.954, respectively. Intraobserver surface area analysis yielded a mean difference of 0.010, LA from -0.764 to 0.785 and an SD of 0.395, and an interobserver analysis mean difference of 0.028, LA from -0.642 to 0.698 and SD of 0.342. The respective ICCs for the intra- and interobserver variations were 0.963 and 0.972.

Conclusions: Micro-CT showed excellent accuracy and reproducibility in the evaluation of mucosal morphometry and surface areas. The improved sensitivity for histological changes is a powerful tool for the diagnosis of celiac disease and for clinical and pharmacological studies.

KEYWORDS

celiac disease, biopsies, histology, diagnosis, micro-CT, imaging

Introduction

Celiac disease (CeD) is an immune-mediated gastrointestinal condition with an estimated prevalence of 1–2% (1). Although the role of serological tests and other surrogate markers for tissue damage in CeD is increasing (2, 3), duodenal histopathology remains the reference standard for the diagnosis and evaluation of treatment response, as well as for the emerging pharmaceutical trials (4, 5). Histological assessment, however, is complicated by the variable quality of the endoscopic specimens and patchiness of the mucosal lesion (6). Moreover, precise orientation of the biopsy cuttings needed for reliable measurements is problematic and often not achieved (7, 8). These challenges have led to significant intra- and interobserver variation in the interpretation of histology, emphasizing the need for more accurate morphometric readouts (3, 4, 6, 8–13).

X-ray microtomography (micro-CT) is an imaging technique enabling comprehensive virtual modeling of a tissue sample with high resolution and with staining methods, also for soft tissue (4, 15). The resulting 3D reconstructions can be freely rotated and digitally cut and quantified, making the method particularly promising for morphometric measurements. We recently optimized a micro-CT protocol for human-derived intestinal biopsies, and, according to the preliminary results, the method provides superior accuracy compared with traditional histology (16). Moreover, we were able to measure mucosal surface areas from the 3D reconstructions for biologically more informative and more sensitive readouts. These findings suggest that micro-CT is a promising tool for the assessment of duodenal mucosa, but further validation is required before widespread clinical use.

We here proceed to further study and validate the diagnostic accuracy of the micro-CT imaging by utilizing small-bowel mucosal samples representing variable degrees of histological changes taken from a large cohort of CeD patients and controls.

Materials and methods

Patient and study design

The study was carried out at Tampere University and Tampere University Hospital. Duodenal biopsies for micro-CT imaging were chosen from 58 individuals who had undergone esophagogastroduodenoscopy for the diagnosis or follow-up of CeD or due to other clinical indication and had given permission for the samples to be used for research purposes. The aim was to collect histologic changes of variable degrees, ranging from morphologically normal intestinal villi to completely flat duodenal mucosa, thus representing both non-CeD patients and different stages of disease activity. Besides the endoscopy, CeD-associated serology and HLA genetics were also measured. Subjects having received a CeD diagnosis started on a strict gluten-free diet after guidance by a dietician, and a control visit including a repeat biopsy was scheduled approximately 1 year. The biopsies obtained were used for the study analyses as described below.

The Regional Ethics Committee of Pirkanmaa Hospital District approved the original patient recruitment. Written informed consent was requested from all subjects participating in the research projects, and the Declaration of Helsinki was adhered to.

Serology and genetics

Serum IgA-class tissue transglutaminase antibodies (TGA) were measured by commercial enzyme-linked immunosorbent assay (Phadia AB, Uppsala, Sweden), considering values ≥ 5.0 U/ml positive. Serum endomysium antibodies (EmA) were measured by an in-house immunofluorescence method as described elsewhere in detail (17). A titer 1:5 for EmA was considered positive and further diluted up to 1:4,000. Gene alleles encoding the CeD-associated HLA-DQ2 and HLA-DQ8 haplogenotypes were analyzed using either the PSM DQB1 kit (Olerup SSP AB, Saltsjöbaden, Sweden) or the tag SNP method. Lack of these

haplotypes has a high negative predictive value for the presence of CeD (1).

Histology

At least four forceps mucosal biopsies were taken from the second or third part of the duodenum for routine diagnostics using a standard endoscope. Several additional samples were taken for research purposes. For histology, the biopsies were with formalin, embedded in paraffin, cut into 2- μ m slices, and stained with hematoxylin-eosin (H&E). In addition to conventional grouped classification, the mucosal specimens were assessed with quantitative histomorphometry applying our validated standard operating procedures (9). Only biopsy sections with longitudinally cut villi-crypt pairs were accepted for the measurement of histomorphometry and villus height/crypt depth ratio (VH : CrD), and recuttings were made until an acceptable orientation was obtained (Figures 1A,B). VH : CrD is reported as an average of three distinct crypt-villous pairs (9). CeD diagnosis was based on the determination of crypt hyperplasia and villous atrophy (VH : CrD <2.0) in the routine histological assessment by a hospital pathologist. Potential CeD was defined as seropositivity to TGA and/or EMA and presence of HLA-DQ2/DQ8 with non-diagnostic duodenal histology in the aforesaid histopathological evaluation (19).


Micro-CT imaging

Paraffin-embedded duodenal samples were used for cutting angles for exact morphometric measurements of the micro-CT. Excess paraffin around the actual tissue was

removed from the biopsies before imaging, and the remaining sample was placed in an iodine-ethanol solution (I₂E) for 12 h to enhance the intrinsically low soft tissue contrast (16). The I₂E solution was made by dissolving solid iodine (207772, Sigma-Aldrich, MO) in absolute ethanol to achieve a concentration of 0.1 mg/ml. Although tissue saturation could theoretically be faster in fresh biopsies, according to our proof-of-concept study the paraffin-embedded samples showed fewer sample-movement artifacts with sufficient saturation (16). The contrast-enhanced samples were positioned in a 1-ml plastic syringe between two rubber pistons for mechanical stabilization, and the syringe was filled with the I₂E to prevent outward diffusion of the contrast agent. A set of images (drift file) was collected from axed angle during the imaging process in order to monitor chemical and mechanical stability.

The imaging was performed by the commercial MicroXCT-400 device (Xradia; Carl Zeiss AG, CA, USA) applying an acceleration voltage of 100 kV and a 10-W source power without filtering (16). The settings used provide adequate image quality with a practicable imaging time, and no beam hardening was observed. A total of 1,600 separate X-ray projections were obtained uniformly 360° around each sample with a 5-s exposure time for each image. An X-ray detection scintillator with 10 \times objective was used with binning 2, delivering a voxel size of approximately 2 μ m. For 3D image creation, the data were reconstructed by XMReconstructor 8.1.6599 software (Xradia). The 3D reconstructions obtained could be freely rotated and digitally cut into slices, always with optimal

cutting angles for exact morphometric measurements of the villi and crypts (Figure 1Q).



Surface area measurements with micro-CT

The original protocol has been described elsewhere (16). Some modifications were made to enable a more efficient workflow. Briefly, the first part of the analysis was done utilizing Avizo 2020.2 software (Thermo Fisher Scientific, Waltham, MA, USA). First, a rectangular cuboid was selected from the imaging data. The volume has side lengths of 0.5 mm, and the depth goes through the sample. The volume to be analyzed was selected perpendicular to the vintuopt interface (Figure 1D). The non-local means filter was used to smooth the inaccuracies caused by noise in the imaging data. The selected volume was segmented to the sample and background with thresholding. The second part was done with an in-house Matlab program (MathWorks, Inc., Natick, MA, USA). The surface was extracted from the segmented volume. The Crofton formula was used, and the effective surface area was calculated by dividing the measured area by the theoretical area. During the process, the user selects the location of the analysis and the threshold level for the segmentation and everything else is automated.

Statistics

Patient characteristics are given either as number of cases and percentages or as medians with lower and upper quartiles. Intraobserver and interobserver variations for VH : CrD and surface area were analyzed by the Bland-Altman method, in which the differences between two measurements are plotted against the averages of the two explicit measurements (17). The results are reported as the mean difference between the measurements and limit of agreement, calculated as the mean difference \pm twice the standard deviation (SD) of the differences. Twice the SD was chosen as the margin of error. (In the scatterplot, the X-axis shows the mean of the results and the Y-axis the difference between the two intra- or interobserver measurements. Agreement on the measurements was evaluated

with the intraclass correlation coefficient (ICC). For better visualization of the measurements, correlation scatterplots are also shown. SPSS Statistics version 27.0.1 (IBM, Armonk, NY, USA) was used for the statistical analyses.

Results

Altogether, 19 of the participants had CeD, six potential CeD, and 17 were treated CeD in the routine histology, while 16 were non-CeD controls (Table 1). Women were overrepresented in all groups, and the median age ranged from 30 to 50 years. All CeD and potential CeD patients presented with HLA DQ2/DQ8, whereas these were lacking from 31.2% of the controls. Similarly, all subjects with untreated or potential CeD, as well as three (18%) of the treated patients, had positive TGA and/or EmA, whereas the controls were invariably seronegative (Table 1).

By definition, untreated CeD patients had clearly reduced VH : CrD in the routine histology, whereas the median ratio was at a normal level in treated patients and in those with potential CeD, and even higher among the controls (Table 2). The results of the micro-CT measurements reflected these findings, although the median values of other groups except untreated CeD patients were lower (Table 2). Of note, four out of the six cases with potential CeD had VH : CrD below 2.0, which is often considered diagnostic for CeD.

The Bland-Altman analysis for micro-CT morphometry demonstrated a small mean difference for both intra- and interobserver VH : CrD measurements, indicating absence of systematic error (Figure 2, Table 3). The corresponding limits of agreement were from -0.397 to 0.375 and from -0.719 to 0.537, respectively, and the ICCs were excellent at 0.981 and 0.954, respectively (Table 3). The error ranges indicated by twice the standard deviation were 0.397 for intraobserver VH : CrD and 0.536 for interobserver VH : CrD.

The mean differences for the intra- and interobserver micro-CT measurements of the mucosal surface area were even lower than those of VH : CrD, again suggesting a negligible systematic error (Figure 3, Table 3). The limits of agreement were from -0.764

TABLE 1 Clinical and serological findings and celiac disease-associated genetics of the 58 study patients.

	Celiac disease, n = 19	Treated celiac disease, n = 17	Potential celiac disease, n = 6	Non-celiac controls, n = 16
Age, median (range), years	44 (33-58)	37 (30-56)	50 (44-63)	30 (24-41)
Females, n (%)	17 (89.5)	12 (70.6)	5 (83.3)	12 (75.0)
HLA DQ2/8, n (%)	19 (100)	17 (100)	6 (100)	11 (68.8)
TGA, ² median (quartiles), U/L	57.1 (5.8, 101)	2.1 (0.3, 3.0)	6.3 (4.2, 8.0)	0 (0, 0.2)
TGA positive, n (%)	18 (94.7)	2 (11.8)	4 (66.6)	0 (0)
EmA positive, n (%)	17 (89.5)	4 (23.5)	6 (100)	0 (0)

¹Positive EmA and/or TGA and HLA DQ2/8 with normal duodenal villi in routine histologic evaluation. ²Reference <5.0 U/l, highest reported value 101 U/l. EmA, endomysial antibodies; HLA, human leukocyte antigen; TGA, tissue transglutaminase antibodies.

TABLE 2 Histological features and micro-CT findings of the 58 study patients.

	Celiac disease, n = 19		Treated celiac disease, n = 17		Potential celiac disease ¹ , n = 6		Non-celiac controls, n = 16	
	Median	Range	Median	Range	Median	Range	Median	Range
VH/CrD, histology	0.2	0.1-1.0	2.6	2.3-3.2	2.6	2.1-3.3	3.3	2.7-3.9
VH/CrD, CT	0.2	0.1-1.1	2.1	1.6-2.8	1.7	1.5-2.8	2.4	1.6-2.8
Surface area/CT	1.4	1.1-2.5	3.9	3.1-4.5	3.5	3.0-3.8	4.7	3.9-5.2

¹Positive celiac disease serology and HLA DQ2/8 with non-diagnostic histology at theoretical completely at area of 1.0. CT, computed tomography; VH/CrD, villous-height crypt depth ratio.

to 0.785 for the intraobserver analyses and from -0.642 to 0.698 for the interobserver analyses, and ICCs 0.963 and 0.972, respectively (Table 3).

Discussion

Both intraobserver and interobserver reproducibility for the morphometric measurements with micro-CT proved excellent with practically no systematic error between readers. For comparison, the most widely used grouped classifications in conventional histology, although fairly good for distinguishing between severe atrophy and healthy mucosa, have demonstrated

lesions commonly seen in CeD patients (3, 22-24). Ideally, measurement of quantitative VH : CrD can provide more accurate and reproducible results, particularly when special emphasis is placed on correct orientation of the biopsy cuttings (Figure 1B) (7, 9, 13, 23). However, acquiring acceptable sections for histomorphometry requires skilled personnel and is laborious and time-consuming (9, 13), making it impractical for clinical routine. In fact, achieving an appropriate cutting angle may not be possible even with rigorous effort due frequently to tissue availability. By contrast, micro-CT allows fast, accurate, and reproducible digital cutting and morphometric measurement with optimal angles (Figure 1C).



morphometric cutoff for the CeD diagnosis remains debatable even interobserver agreements. The novel technology provides a robust tool for assessing diagnostically ambiguous cases in with traditional histology (14, 24, 27–29). The villous length may also vary depending on the anatomical location within the intestine CeD and for academic and pharmaceutical trials. Future (29), emphasizing the use of standardized sampling sites in research could explore the performance of micro-CT longitudinal studies. As regards the surface area, here the lowest particularly in diagnostically challenging situations such as factor among the non-CeD controls was 3.9, but additional studies potential CeD and for the diagnosis of other intestinal diseases specically addressing the diagnostic value are needed. Notably, involving morphological lesions. four subjects with potential CeD already had diagnostic VH : CrD with micro-CT imaging, and some treated patients showed values indicating incompletely mucosal recovery, a condition known to be common even in case of strict dietary adherence (6). Although the same cutoffs may not apply directly, this nevertheless suggests a superior sensitivity of micro-CT for borderline mucosal lesions compared with the conventional histology. Further studies on this issue and optimal VH : CrD cutoffs are however called for.

There are several ongoing studies testing pharmaceutical therapies for CeD (31). Taavela et al. demonstrated improved accuracy for quantitative VH : CrD compared with grouped classification to detect minor mucosal changes during prospective intervention, with a change of 0.4 being considered significant according to the margins of error (13). Our results are in line with this, which was to be expected as the same morphometric outcome was used, but with micro-CT, this was accomplished with much less effort. Given the abovementioned reduced random variation and the exponential nature of surface area compared with morphometry, it could be expected to be an even more accurate and sensitive method. The margin of error (2SD) for the surface area measurement was approximately 0.8, which should be confirmed in future clinical studies.

Our main strengths were the well-defined cohort of CeD and non-CeD individuals, representing a wide range of histological damage, and the use of previously optimized procedures for the imaging. As a limitation, the study sample size was only moderate, although we considered it sufficient for the conducted validation analyses. Furthermore, micro-CT also has some technical limitations that should be addressed. First, the resolution—although adequate for the morphometric analyses—is lower than that with histology. Second, we did not quantify the degree of mucosal inflammation at this point, but this should be possible in the future utilizing special contrast agents (30). In fact, the mucosal cell count is less sensitive for reading errors even with conventional histology (32, 33). Finally, the equipment and expertise needed for micro-CT is available only in specialized centers, which may increase costs and limit the wide-scale use of the methodology, but it should be quite straightforward to ship the biopsies for centralized imaging.

Data availability statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy and ethical restrictions. Requests to access the datasets should be directed to kalle.kurppa@tuni.fi.

Ethics statement

The studies involving human participants were reviewed and approved by The Regional Ethics Committee of Pirkanmaa Hospital District. The participants provided their written informed consent to participate in this study.

Author contributions

All the authors listed met the authorship criteria. JV, KKu, MH, JT, and HH designed the study and contributed to the data analysis and interpretation and drafting of the manuscript. KL, JT, KKa, PS, and JH critically reviewed the analysis and made a substantial additional contribution to the manuscript. All authors reviewed the manuscript and approved the final version.

Funding

The work was funded by the Academy of Finland, the Finnish Funding Agency for Technology and Innovation, the Sigrid Juselius Foundation, the Foundation for Pediatric Research, the Päivikki and Sakari Sohlberg Foundation, the University Consortium of Seinäjoki, and the Competitive State Research Financing of the Expert Area of Tampere University Hospital. The funders had no role in the design or conduct of the study.

Conclusion

Measurement of small-bowel mucosal morphology and surface area using digitalized 3D micro-CT reconstructions is accurate and reproducible with excellent intraobserver and

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or the claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Lindfors K, Ciacci C, Kurppa K, Lundin K, Makharia G, Mearin L, et al. Coeliac disease. *Nat Rev Dis Prim* (2019) 5(1):3. doi:10.1038/s41572-018-0054-z
- Popp A, Kivelä L, Fuchs V, Kurppa K. Diagnosing celiac disease: Towards wide-scale screening and serology-based criteria. *Gastroenterol Res Pract* (2019) 2019:2916024. doi:10.1155/2019/2916024
- Husby S, Koletzko S, Korponay-Szabó Z, Kurppa K, Mearin L, Ribes-Koninckx C, et al. European Society paediatric gastroenterology, hepatology and nutrition guidelines for diagnosing coeliac disease. *J Pediatr Gastroenterol Nutr* (2020) 70(1):14–56. doi:10.1097/MPG.0000000000002497
- Ludvigsson J, Ciacci C, Green PH, Kaukinen K, Korponay-Szabó Z, Kurppa K, et al. Outcome measures in celiac disease trials: The Tampere recommendations. *Gut* (2018) 67(8):1414–24. doi:10.1136/gutjnl-2017-314853
- Schuppan D, Mäki M, Lundin K, Isola J, Friesing-Sosnik T, Taavela J, et al. A randomized trial of a transglutaminase 2 inhibitor for celiac disease. *Am J Med* (2021) 385(1):35–45. doi:10.1056/NEJMoa2032441
- Ravelli A, Villanacci V, Monfredini C, Martinazzi S, Grassi V, Manenti S. How patchy is patchy villous atrophy? Distribution pattern of histological lesions in the duodenum of children with celiac disease. *Am J Gastroenterol* (2010) 105(9):2103–10. doi:10.1038/ajg.2010.153
- Popp A, Arvola T, Taavela J, Kivelä L, Ene A, Laurila K, et al. Nonbiopsy approach for celiac disease is accurate when using exact duodenal histomorphometry: Prospective study in 2 countries. *Clin Gastroenterol* (2020) 55(3):227–32. doi:10.1097/MCG.0000000000001349
- Werkstetter K, Korponay-Szabó Z, Popp A, Villanacci V, Salemm M, Heilig G, et al. Accuracy in diagnosis of celiac disease without biopsies in clinical practice. *Gastroenterology* (2017) 153(4):924–5. doi:10.1053/j.gastro.2017.06.002
- Taavela J, Koskinen O, Huhtala H, Lähdeaho ML, Popp A, Laurila K, et al. Validation of morphometric analyses of small-intestinal biopsy readouts in celiac disease. *PLoS One* (2018) 8(10):e76163. doi:10.1371/journal.pone.0076163
- Penny H, Raju S, Lau M, Marks L, Baggus E, Bai J, et al. Accuracy of a jejunal biopsy approach for the diagnosis of coeliac disease across different adult cohorts. *Gut* (2020) 70(5):874–83. doi:10.1136/gutjnl-2020-320913
- Ylönen V, Lindfors K, Repo M, Huhtala H, Fuchs V, Saavalainen P, et al. Non-biopsy serology-based diagnosis of celiac disease in adults is accurate with different commercial kits and pre-test probabilities. *Nutrients* (2020) 12(9):2736. doi:10.3390/nu12092736
- Sarna V, Skodje G, Reims H, Risnes L, Dahal-Koirala S, Sollid LM, et al. HLA-DQ: Gluten tetramer test in blood gives better detection of coeliac patients than biopsy after 14-day gluten challenge. *Gut* (2018) 67(9):1600–3. doi:10.1136/gutjnl-2017-314461
- Adelman DC, Murray J, Wu TT, Mäki M, Green PH, Kelly CP. Measuring change in small intestinal histology in patients with celiac disease. *Am J Gastroenterol* (2018) 113(3):339–7. doi:10.1038/ajg.2017.480
- Happel C, Klose C, Witton G, Angrisani G, Wienecke S, Groos S, et al. Non-destructive, high-resolution 3-dimensional visualization of a cardiac defect in the chick embryo resembling complex heart defect in humans using micro-computed tomography: Double outlet right ventricle with left juxtaposition of atrial appendages. *Circulation* (2010) 122(22):e564. doi:10.1161/circulationaha.110.977884
- Mizutani R, Suzuki Y. X-Ray microtomography in biology. *Micron* (2012) 42(6):553–9. doi:10.1016/j.micron.2011
- Virta J, Hannula M, Tamminen I, Lindfors K, Kaukinen K, Popp A, et al. X-Ray microtomography is a novel method for accurate evaluation of small-bowel mucosal morphology and surface area. *Clin Res* (2020) 10(1):13164. doi:10.1038/s41598-020-69487-w
- Kurppa K, Paavola A, Collin P, Sievänen H, Laurila K, Huhtala H, et al. Benefits of a gluten-free diet for asymptomatic patients with serologic markers of celiac disease. *Gastroenterology* (2014) 147(3):614–17.e1. doi:10.1053/j.gastro.2014.05.003
- Monsuur A, Bakker P, Zhernakova A, Pinto D, Verduijn W, Romanos J, et al. Effective detection of human leukocyte antigen risk alleles in celiac disease using tag single nucleotide polymorphism. *PLoS One* (2009) 3(5):e2270. doi:10.1371/journal.pone.0002270
- Ludvigsson J, Leif D, Bai J, Biagi F, Fasano A, Green PH, et al. The Oslo definitions for coeliac disease and related terms. *Gut* (2013) 62(1):43–52. doi:10.1136/gutjnl-2011-301346
- Bartko JJ. The intraclass correlation coefficient as a measure of reliability. *Psychol Rep* (1966) 1:311. doi:10.2466/pr0.1966.19.1.3
- Bland JM, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. *BMJ* (1986) 1(8476):307–10. doi:10.1016/S0140-6736(86)90837-8
- Arguelles-Grande C, Tennyson C, Lewis S, Green P, Bhagat G. Variability in small bowel histopathology reporting between different pathology practice settings: Impact on the diagnosis of coeliac disease. *Clin Pathol* (2012) 65(3):247. doi:10.1136/clinpath-2011-200372
- Corazza G, Villanacci V, Zambelli C, Milione M, Luinetti O, Vindigni C, et al. Comparison of the interobserver reproducibility with different histologic criteria used in celiac disease. *Clin Gastroenterol Hepatol* (2007) 5(7):834–3. doi:10.1016/j.cgh.2007.03.019
- Mubarak A, Nikkels P, Houwen R, Ten Kate F. Reproducibility of the histological diagnosis of celiac disease. *Am J Gastroenterol* (2011) 46(9):1067–3. doi:10.3109/00365521.2011.589471
- Easlon H, Bloom A. Easy leaf area: Automated digital image analysis for rapid and accurate measurement of leaf area. *Plant Sci* (2014) 2(7):1400033. doi:10.3732/apps.1400033
- Meinhard E, Wadbrook D, Risdon R. Computer card morphometry of the mucosa in various childhood enteropathies with special reference to intraepithelial lymphocytes. *J Pediatr Gastroenterol Nutr* (1982) 1(4):523–31. doi:10.1097/00005176-198212000-00012
- Kaukinen K, Peräaho M, Lindfors K, Partanen J, Woolley N, Pikkarainen P, et al. Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. *Aliment Pharmacol Ther* (2007) 25(10):1237–5. doi:10.1111/j.1365-2036.2007.03311.x
- Daveson J, Popp A, Taavela J, Goldstein K, Isola J, Truitt K, et al. Baseline quantitative histology in therapeutic trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten-free diet. *Gastroenterology* (2020) 2(1):230. doi:10.1002/ygh2.380
- Ashton J, West J, Badesi C, Vivo small animal micro-CT using nanoparticle contrast agents. *Front Pharmacol* (2015) 6:256. doi:10.3389/fphar.2015.00256
- Kivelä L, Caminero A, Leif D, Pinto-Sanchez M, Tye-Din J, Lindfors K. Current and emerging therapies for coeliac disease. *Nat Rev Gastroenterol Hepatol* (2020) 18(3):189–95. doi:10.1038/s41575-020-00378-1
- Aziz I, Peerally M, Barnes JH, Kandasamy V, Whiteley J, Partridge D, et al. The clinical and phenotypical assessment of seronegative villous atrophy: a prospective UK centre experience. *Gut* (2017) 66(9):1567–72. doi:10.1136/gutjnl-2016-312271
- Corazza G, Villanacci V. Coeliac disease. *Clin Pathol* (2005) 58(6):573–4. doi:10.1136/jcp.2004.023978